Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lohmueller, Jason J ^a   Sato, Shuji ^b   Popova, Lana ^b   Chu, Isabel M ^b   Tucker, Meghan A ^b   Barberena, Roberto ^b   Innocenti, Gregory M ^b   Cudic, Mare ^c   Ham, James D ^a,d   Cheung, Wan Cheung ^b,e   Polakiewicz, Roberto D ^b   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CELL SIGNALING TECHNOLOGY   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d CARNEGIE MELLON UNIVERSITY   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER VACCINE; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G; MUCIN 1;

ADULT; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; BREAST TUMOR; CELL LINE; CYTOTOXICITY; FEMALE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; MALE; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODY AFFINITY; BASE SEQUENCE; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FEMALE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MALE; MCF-7 CELLS; MIDDLE AGED; MUCIN-1; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84983348042     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31740     Document Type: Article

References (49)

1. Sliwkowski, M. X. & Mellman, I. Antibody therapeutics in cancer. Science 341, 1192-1198 (2013).
2. Rogers, L. M., Veeramani, S. & Weiner, G. J. Complement in monoclonal antibody therapy of cancer. Immunol. Res. 59, 203-210 (2014).
3. Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
4. Clynes, R. a, Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-4446 (2000).
5. LoRusso, P. M., Weiss, D., Guardino, E., Girish, S. & Sliwkowski, M. X. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 17, 6437-6447 (2011).
6. Staerz, U. D., Kanagawa, O. & Bevan, M. J. Hybrid antibodies can target sites for attack by T cells. Nature 314, 628-631 (1985).
7. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
8. Vlad, A. M., Kettel, J. C., Alajez, N. M., Carlos, C. A. & Finn, O. J. MUC1 Immunobiology: From Discovery to Clinical Applications. Adv. Immunol. 82, 249-293 (2004).
9. American Cancer Society. Cancer Facts & Figures 2013. Am. Cancer Soc. 2010 (2013).
10. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site, 2013. http//seer.cancer.gov/csr/1975-2010 (Accessed June 08, 2013) (2011).
11. Couraud, S., Zalcman, G., Milleron, B., Morin, F. & Souquet, P. J. Lung cancer in never smokers-A review. Eur. J. Cancer 48, 1299-1311 (2012).
12. Moyer, V. A. Screening for prostate cancer: US preventive services task force recommendation statement. Ann. Intern. Med. 157, 120-134 (2012).
13. Turner, M. S., McKolanis, J. R., Ramanathan, R. K., Whitcomb, D. C. & Finn, O. J. Mucins in gastrointestinal cancers. Cancer Chemother. Biol. Response Modif. 21, 259-274 (2003).
14. Baldus, S. E. et al. MUC1 and Nuclear β -Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis. Clin. Cancer Res. 10, 2790-2796 (2004).
15. Ahmad, R. et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor- B p65 transcription factor. Cancer Res. 69, 7013-7021 (2009).
16. Budiu, R. A. et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol. Immunother. 60, 975-984 (2011).
17. Cramer, D. W. et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14, 1125-1131 (2005).
18. Soares, M. M., Mehta, V. & Finn, O. J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555-6563 (2001).
19. Beatty, P. L., Narayanan, S., Gariépy, J., Ranganathan, S. & Finn, O. J. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev. Res. 3, 438-446 (2010).
20. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J. & Lotze, M. T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298-304 (1996).
21. Ramanathan, R. K. et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54, 254-264 (2005).
22. Lepisto, A. J. et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 6, 955-964 (2008).
23. Kimura, T. et al. MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev. Res. 6, 18-26 (2013).
24. Hwang, W. Y. K. & Foote, J. Immunogenicity of engineered antibodies. Methods 36, 3-10 (2005).
25. Cheung, W. C. et al. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol. 30, 447-452 (2012).
26. Sato, S. et al. Proteomics-directed cloning of circulating antiviral human monoclonal antibodies. Nat. Biotechnol. 30, 1039-1043 (2012).
27. Price, M. R. et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol. 19 Suppl 1, 1-20 (1998).
28. Guan, H. H. et al. Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses. Bioconjug. Chem. 9, 451-458 (1998).
29. Danielczyk, A. et al. PankoMab: A potent new generation anti-tumour MUC1 antibody. Cancer Immunol. Immunother. 55, 1337-1347 (2006).
30. Thie, H. et al. Rise and fall of an anti-MUC1 specific antibody. PLoS One 6 (2011).
31. Caldas, C. et al. Humanization of the anti-CD18 antibody 6.7: An unexpected effect of a framework residue in binding to antigen. Mol. Immunol. 39, 941-952 (2003).
32. Ibrahim, N. K. et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin. Cancer Res. 17, 6822-6830 (2011).
33. Pegram, M. D. et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 11, R73 (2009).
34. de Bono, J. S. et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: Evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol. 15, 1825-1833 (2004).
35. Nicholson, S. et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother. 53, 809-816 (2004).
36. Verheijen, R. H. et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24, 571-578 (2006).
37. DeNardo, S. J. et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J. Nucl. Med. 38, 1180-1185 (1997).
38. Kramer, et al. et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 4, 1679-1688 (1998).
39. Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006).
40. Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26-31 (2013).
41. Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24 (2006).
42. Silk, A. W., Schoen, R. E., Potter, D. M. & Finn, O. J. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol. Immunol. 47, 52-56 (2009).
43. Alajez, N. M., Schmielau, J., Alter, M. D., Cascio, M. & Finn, O. J. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 105, 4583-4589 (2005).
44. Chen, X., Gao, W., Gambotto, A. & Finn, O. J. Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: Potential for universal and safe cancer immunotherapy. Cancer Immunol. Immunother. 58, 977-987 (2009).
45. Fontenot, J. D. et al. Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. J. Biomol. Struct. Dyn. 13, 245-260 (1995).
46. Turatti, F. et al. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J. Immunother. 30, 684-693 (2007).
47. Altschuler, Y. et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol. Biol. Cell 11, 819-831 (2000).
48. Hisatsune, A. et al. Internalization of MUC1 by anti-MUC1 antibody from cell membrane through the macropinocytotic pathway. Biochem. Biophys. Res. Commun. 388, 677-682 (2009).
49. Rodriguez, M. C. et al. Thermodynamic Switch in Binding of Adhesion/Growth Regulatory Human Galectin-3 to Tumor-Associated TF Antigen (CD176) and MUC1 Glycopeptides. Biochemistry 54, 4462-4474 (2015).